Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients

J. P. Hammerstad, W. R. Woodward, J. G. Nutt, S. T. Gancher, G. A. Block, G. Cyhan

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.

Original languageEnglish (US)
Pages (from-to)429-434
Number of pages6
JournalClinical neuropharmacology
Volume17
Issue number5
DOIs
StatePublished - Jan 1 1994

Keywords

  • Controlled release levodopa/carbidopa (Sinemet CR) 25/100
  • Levodopa
  • Parkinson's disease
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients'. Together they form a unique fingerprint.

  • Cite this